InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | 2026-05-20 | Kosasa Thomas | Director | Purchase | 268.8K | $0.93 | $250K | 16.93M | View ↗ | |
| 2026-04-23 | 2026-04-24 | Kosasa Thomas | Director | Purchase | 280.9K | $0.89 | $250K | 16.66M | View ↗ | |
| 2026-04-01 | 2026-04-24 | Yu Jeffrey | Director & Chief Medical Officer | Purchase | 903.6K | $0.83 | $750K | 8.23M | View ↗ | |
| 2026-02-06 | 2026-04-24 | Kosasa Thomas | Director | Purchase | 595.2K | $0.84 | $500K | 16.38M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $1.2M | — |
| Total revenue | $1.3M+329.5% | $292K+104.2% | $143K-87.6% | $1.2M | — |
| Cost of revenue | $1.9M+101.5% | $924K-19.7% | $1.1M-24.0% | $1.5M | — |
| Gross margin | -$503K-79.0% | -$281K-117.8% | -$129K+64.2% | -$361K | — |
| General and administrative | $6.4M-9.3% | $7.0M+98.3% | $3.5M-59.5% | $8.8M | — |
| Sales and marketing | $1.3M+53.3% | $830K-25.6% | $1.1M+16.4% | $958K | — |
| Research and development | $1.5M+3.3% | $1.5M-29.0% | $2.1M+116.8% | $953K | — |
| Total operating expenses | $9.2M-1.7% | $9.3M+38.7% | $6.7M-39.2% | $11.1M | — |
| Loss from operations | -$9.7M-0.6% | -$9.6M-40.2% | -$6.9M+40.0% | -$11.4M-1851.7% | -$585K |
| Interest expense | $67K-54.4% | $147K+1236.4% | $11K-97.3% | $403K | — |
| Change in fair value of warrants | $56K+722.2% | -$9K+93.0% | -$129K+97.1% | -$4.5M-171.0% | $6.3M |
| Change in fair value of convertible notes | -$1.3M-259.0% | $808K | — | — | — |
| Change in fair value of crypto assets – Bitcoin | $945K+218.4% | -$798K | — | — | — |
| Realized gain on sale of crypto assets – Bitcoin | -$922K-668.3% | -$120K | — | — | — |
| Change in fair value of SEPA derivative liabilities | -$216K-149.8% | $434K | — | — | — |
| Gain on troubled debt restructurings | -$5.6M | — | — | — | — |
| Loss on extinguishment of debt | $41K | — | — | — | — |
| Other expense | $16K-73.3% | $60K+76.5% | $34K-27.4% | $47K | — |
| Total other (income) expense, net | -$6.9M-1415.5% | $522K-98.1% | $26.9M+617.9% | -$5.2M-731.3% | -$625K |
| Loss before income taxes | -$2.8M+72.4% | -$10.1M+70.0% | -$33.8M | — | $5.1M |
| Income tax expense | $1K-50.0% | $2K-88.9% | $18K | — | -$215K |
| Net loss | -$2.8M+72.3% | -$10.1M+70.0% | -$33.8M-442.2% | -$6.2M-221.3% | $5.1M |
| Basic net loss per common share outstanding | -$60+83.3% | -$360+92.3% | -$5K | — | $0.44 |
| Diluted net loss per common share outstanding | -$60+83.3% | -$360+92.3% | -$5K | — | $0.44 |
| Basic weighted average number of common shares outstanding | $44.55B+58.7% | $28.08B+286.1% | $7.27B | — | $8.3M |
| Diluted weighted average number of common shares outstanding | $44.55B+58.7% | $28.08B+286.1% | $7.27B | — | $8.3M |
| Subscription Revenue [Member] | |||||
| Data Delivery Revenue [Member] | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
OneMedNet Goes Live with 80 Million Patient Journeys and Billions of Records
OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data
OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI
OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights